Addition of PD-1/PD-L1 inhibitors to chemotherapy for triple-negative breast cancer: a meta-analysis

Overview of attention for article published in Frontiers in oncology, February 2024

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

twitter: 4 X users

Readers on

mendeley: 3 Mendeley

Summary X

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 24,123 followers.

RT @FrontOncology: New research: Addition of PD-1/PD-L1 inhibitors to chemotherapy for triple-negative breast cancer: a meta-analysis: Back…

10 Feb 2024

Reply Repost Favourite

New research: Addition of PD-1/PD-L1 inhibitors to chemotherapy for triple-negative breast cancer: a meta-analysis: Background In recent years, the addition of immune checkpoint inhibitors (ICI) to chemotherapy (CT) has become a research… https://t.co/iu3

10 Feb 2024

Reply Repost Favourite

RT @gedefo_sefh: PD1/PD-L1 triple negative breast cancer https://t.co/HW3tvGaVdO

09 Feb 2024

Reply Repost Favourite

PD1/PD-L1 triple negative breast cancer https://t.co/HW3tvGaVdO

09 Feb 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.